Stephanie Mahooty
Adult Health · Albuquerque, NMNPI 1922399542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $31.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Nxstage Medical, Inc.$528
- Amgen$457
- Daiichi Sankyo Inc.$423
- Bayer$417
- Vifor Pharma, Inc.$317
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,553100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $1,106 |
| Nxstage Medical, Inc. | 7 | $528 |
| Amgen(2 entities) | 7 | $457 |
| Daiichi Sankyo Inc. | 33 | $423 |
| Bayer | 13 | $417 |
| Vifor Pharma, Inc. | 14 | $317 |
| Travere Therapeutics, Inc. | 8 | $295 |
| Akebia Therapeutics Inc | 3 | $257 |
| Novo Nordisk | 4 | $250 |
| Otsuka America Pharmaceutical, Inc. | 10 | $236 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $193 |
| GSK | 3 | $161 |
| Mozarc Medical US LLC | 5 | $155 |
| Fresenius USA Marketing, Inc. | 8 | $140 |
| Novartis | 6 | $122 |
| Medtronic | 2 | $117 |
| Sanofi | 2 | $99 |
| Aurinia Pharma U.S., Inc. | 3 | $56 |
| Calliditas Therapeutics US Inc. | 3 | $55 |
| Boehringer Ingelheim | 3 | $45 |
| W. L. Gore & Associates, Inc. | 1 | $31 |
| Cormedix Inc. | 1 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Abbott | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$249
- LOKELMA$248
- FARXIGA$246
- Vafseo$233
- Tavneos$216
- Filspari$136
- Ozempic$116
- PUREFLOW SL$109
- NXSTAGE SYSTEM ONE$109
- KRYSTEXXA$108
How this compares
$5,559 in reported general payments places this provider in the 95th percentile of 52 adult health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 201 | $152,828 |
| VelphoroSucroferric Oxyhydroxide | 40 | $128,680 |
| KerendiaFinerenone | 109 | $79,337 |
| JardianceEmpagliflozin | 39 | $36,487 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $31,541 |
| VeltassaPatiromer Calcium Sorbitex | 17 | $20,272 |
| Lanthanum Carbonate | 19 | $16,453 |
| Sevelamer Carbonate | 59 | $11,373 |
| Calcitriol | 278 | $4,290 |
| Insulin Aspart | 11 | $1,631 |
| Nifedipine ErNifedipine | 69 | $1,592 |
| Amlodipine Besylate | 170 | $1,585 |
| Bumetanide | 64 | $1,573 |
| Lisinopril | 156 | $1,479 |
| Hydralazine Hcl | 77 | $1,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,106 | $184,369227 claims |
| Fresenius USA Marketing, Inc.Velphoro | $140 | $128,68040 claims |
| BayerKerendia | $417 | $79,337109 claims |
| Boehringer IngelheimJardiance | $45 | $36,48739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 adult health providers in New Mexico.
Other adult health in Albuquerque
- Elizabeth EvansAlbuquerque$9K
- Leslie DorkAlbuquerque$7K
- Debra NarcisseAlbuquerque$5K
- Sara RogersAlbuquerque$2K
- Theresa CastlemainAlbuquerque$2K
- Melissa TorresAlbuquerque$2K
- Deborah AnayaAlbuquerque$1K
- Clyde SanchezAlbuquerque$1K
- Sheila MisraAlbuquerque$1K
- Michele HeadAlbuquerque$992
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.